Thx for your re-assuring message. Still puzzled that management created 'expectations' ( at least for me) that something would happen 'shortly'. This means in business lingo : within 2 months. Otherwise they could have announced an update during the 3 Quarterly Company Review,
During the Q Review on August 14, management stated re. Seamless III AML Sapacitabine, I quote ;" We expect to shortly convene the next Drug Safety Monitoring Board or DSMB meeting. The DSMB meets to consider safety after every 100 patients or so have been enrolled and followed.” IMO , the results of this meeting are due any moment now. Wonder if they might be delayed by the current 'shut down' ?